Search: onr:"swepub:oai:DiVA.org:uu-124322" >
Preclinical evaluat...
Preclinical evaluation of innate immunity to baculovirus gene therapy vectors in whole human blood
-
Georgopoulos, Lindsay J. (author)
-
- Elgue, Graciela (author)
- Uppsala universitet,Enheten för klinisk immunologi
-
- Sanchez, Javier (author)
- Uppsala universitet,Enheten för klinisk immunologi
-
show more...
-
Dussupt, Vincent (author)
-
Magotti, Paola (author)
-
Lambris, John D. (author)
-
- Tötterman, Thomas H. (author)
- Uppsala universitet,Enheten för klinisk immunologi
-
Maitland, Norman J. (author)
-
- Nilsson, Bo (author)
- Uppsala universitet,Enheten för klinisk immunologi
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2009
- 2009
- English.
-
In: Molecular Immunology. - : Elsevier BV. - 0161-5890 .- 1872-9142. ; 46:15, s. 2911-2917
- Related links:
-
https://europepmc.or...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Interactions of gene therapy vectors with human blood components upon intravenous administration have a significant effect on vector efficacy and patient safety. Here we describe methods to evaluate these interactions and their effects in whole human blood, using baculovirus vectors as a model. Opsonisation of baculovirus particles by binding of IgM and C3b was demonstrated, which is likely to be the cause of the significant blood cell-associated virus that was detected. Preventing formation of the complement C5b-9 (membrane attack) complex maintained infectivity of baculovirus particles as shown by studying the effects of two specific complement inhibitors, Compstatin and a C5a receptor antagonist. Formation of macroscopic blood clots after 4h was prevented by both complement inhibitors. Pro- and anti-inflammatory cytokines Il-1beta, IL-6, IL-8 and TNF-alpha were produced at variable levels between volunteers and complement inhibitors showed patient-specific effects on cytokine levels. Whilst both complement inhibitors could play a role in protecting patients from aggressive inflammatory reactions, only Compstatin maintained virus infectivity. We conclude that this ex vivo model, used here for the first time with infectious agents, is a valuable tool in evaluating human innate immune responses to gene therapy vectors or to predict the response of individual patients as part of a clinical trial or treatment. The use of complement inhibitors for therapeutic viruses should be considered on a patient-specific basis.
Keyword
- Autographa californica
- Baculovirus
- C5a receptor antagonist
- Complement
- Compstatin
- Gene therapy
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database